The One-Off Treatment That Put Lupus Into Remission

Until now, lupus has had no cure. The 69,000 people in the UK living with the condition — the vast majority of them women — have managed it through lifelong immunosuppression: drugs that reduce the immune system's activity and limit the damage it causes to the body's own tissues, without addressing the underlying dysfunction that drives it. The drugs carry their own risks. The disease continues.

A trial announced today changes what is possible.

Five of six patients with severe lupus have gone into remission after receiving a single dose of CAR-T cell therapy at University College London Hospitals. The trial — the first in the UK to use CAR-T therapy for a condition other than cancer — is led by UCL and UCLH and sponsored by biopharmaceutical company Autolus. Its results represent the most significant development in lupus treatment in decades.

TL;DR

• Five of six patients with severe lupus went into remission within a few months of receiving a single dose of CAR-T cell therapy in an NHS trial led by UCLH and UCL.
• Over an average follow-up of 11 months, participants experienced rapid improvements in markers of the disease including stabilisation or improvement in kidney function — one of the most serious consequences of severe lupus.
• The trial — called CARLYSLE — is an international Phase 1 study involving 12 patients globally. It is the first in the UK to use CAR-T therapy to treat a condition other than cancer.
• The specific therapy is AUTO1/obe-cel, developed by Autolus — a low-toxicity CAR-T designed specifically for autoimmune applications rather than cancer treatment.
• One of the UK patients who received her dose at UCLH described the experience as the first time there had ever been anything for lupus that is a possible cure.
• Professor Karl Peggs, director of UCLH's biomedical research centre, described the findings as truly groundbreaking, while noting that larger studies are needed.
• The same approach may work for other autoimmune conditions including multiple sclerosis — experts believe the immune reset mechanism could transform treatment across the autoimmune disease landscape.

What CAR-T Therapy Is

CAR-T — chimeric antigen receptor T-cell — therapy was developed as a cancer treatment. Its application to autoimmune disease is one of the most significant developments in medicine of the past decade.

The process begins with the patient's own blood. T cells — the immune system's primary soldier cells — are extracted and sent to a laboratory, where they are genetically modified to carry a new receptor on their surface: the chimeric antigen receptor. This receptor is designed to recognise and target a specific cell type. In cancer applications, it targets cancer cells. In lupus, it targets B cells — the white blood cells that produce the antibodies that drive the immune attack on the body's own tissues.

The modified T cells are then returned to the patient's bloodstream in a single infusion. They circulate, find the B cells they have been engineered to target, and destroy them. The aberrant antibody-producing cells that have been driving the lupus are eliminated. The immune system — freed from the B cells that were directing it against healthy tissue — can reset.

> The idea is that you take out a patient's T cells, engineer them to target the autoantibody-producing cells that drive inflammation in lupus, and return them to the patient where they can do their work. Early results from Europe suggest that an apparent reset of the immune response may occur.

> — Dr Frank Koumpouras, Yale School of Medicine

This reset is the concept that makes CAR-T so significant for autoimmune disease. It is not suppressing the immune system. It is removing the specific cells that have been driving the immune system to attack the body — allowing the immune system to restart from a different baseline.

The Origins: From Germany to London

The CAR-T approach to autoimmune disease did not begin with the CARLYSLE trial. It began in Erlangen.

Dr Georg Schett at the University of Erlangen-Nuremberg in Germany treated a severely ill young woman with lupus who had failed all other treatments. After one infusion of CAR-T, she went into remission — and remained in remission, without any other medication, from March 2021. Schett subsequently treated several dozen more patients with lupus and other autoimmune conditions including myositis and scleroderma. The results were described by researchers as shocking — few relapses, remission in conditions that had previously been managed only through lifelong medication.

Those results triggered an explosion of clinical trials globally, including the CARLYSLE trial at UCLH — the first NHS-led trial of CAR-T in autoimmune disease.

The specific therapy used in the CARLYSLE trial — AUTO1/obe-cel — is a low-toxicity CAR-T developed by Autolus, a UCL spin-out biopharmaceutical company that has been developing T-cell therapies for more than a decade. Claire Roddie, UCLH consultant haematologist and UCL Cancer Institute researcher, noted that AUTO1/obe-cel had already shown transformational impact in cancer patients — and the hope is that it will have a similarly significant effect in lupus.

The Patients

The participants in the CARLYSLE trial have spoken publicly about what the treatment means — not only for lupus specifically but for the broader landscape of autoimmune disease.

One of the UK patients who received her dose at UCLH told the Press Association: "I am beyond excited. Up until now, there's never been anything for lupus that is a possible cure."

She described being contacted by the research team and told that the trial was coming to UCLH — and being asked whether she would like to participate. Her response reflects what the finding means for a community of patients who have lived with the certainty that their condition has no endpoint.

"There's so many autoimmune diseases out there, and there are 70,000 lupus patients in the UK, so I hope that the results from this trial come out and it gives people the hope that everybody who has an autoimmune disease will be able to have an end point. Up until now, there's been no cure and no hope of anything, just immunosuppression, which has its own issues. So I hope that this trial gives everybody hope with autoimmune disease, that something's coming their way that will make a massive difference in their lives."

The dream, she said, is to be lupus-free. That would be phenomenal.

What Lupus Is

Lupus — systemic lupus erythematosus, or SLE — is a chronic autoimmune disease in which the immune system attacks the body's own healthy tissues. The resulting inflammation can affect virtually any organ — the kidneys, lungs, heart, brain, joints, and skin. Severity ranges considerably: some people manage their condition with relatively low-level immunosuppression and limited organ involvement; others develop severe, life-threatening complications including nephritis — inflammation of the kidneys that leads to permanent damage.

Around 69,000 people in the UK are thought to have lupus, according to Lupus UK. It affects women significantly more than men — approximately nine women for every one man — and is more prevalent and more severe in people of Black African, Caribbean, and Asian descent.

Current treatment is immunosuppressive: hydroxychloroquine, steroids, and other drugs that reduce the immune system's overall activity, as outlined in NHS guidance on lupus. Belimumab and anifrolumab — more targeted biologics — have been approved in recent years, representing the most significant treatment advances in decades. None of these approaches offer the possibility of remission or cure. They manage the condition without addressing its underlying cause.

The CAR-T approach is the first therapy designed to address that underlying cause — the B cells producing the antibodies that direct the immune attack on the body's own tissues.

The Results: What the Trial Found

Five of six patients with severe lupus went into remission within a few months of receiving a single dose of CAR-T in the CARLYSLE trial. Over an average follow-up of 11 months, participants experienced rapid improvements in markers of the disease — including stabilisation or improvement in kidney function, which had been damaged by lupus.

The kidney finding is clinically significant. Lupus nephritis — kidney inflammation driven by lupus — is one of the most serious complications of the condition and can lead to irreversible kidney damage and dialysis dependence. Stabilisation or improvement in kidney function following a single CAR-T infusion is a finding that would not have been predicted from the existing treatment landscape.

The trial involves 12 patients globally — this is a Phase 1 study, designed primarily to assess safety and feasibility rather than to confirm efficacy at scale. The remission rate of five out of six is a striking signal from a small cohort. Larger trials will be required to confirm the findings — and to establish the duration of remission, the optimal patient selection criteria, and the long-term safety profile of the therapy.

Professor Karl Peggs, director of UCLH's biomedical research centre, described the findings as truly groundbreaking, offering fresh hope to people living with lupus — while emphasising that bigger studies are needed to confirm the potential.

The Broader Implications: Beyond Lupus

The implications of the CARLYSLE results extend beyond lupus specifically.

Experts believe the same CAR-T approach may work for other autoimmune conditions — including multiple sclerosis. The mechanism of resetting the immune system by removing the specific B cell populations driving autoimmune attack is not unique to lupus. It is potentially applicable to any condition in which B cells are the primary driver of immune dysfunction.

The broader autoimmune disease landscape in the UK includes conditions affecting millions of people — rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, type 1 diabetes, and dozens of rarer conditions. The concept of a one-off immune reset that removes the need for lifelong immunosuppression — with its attendant infection risk, organ toxicity, and quality of life impact — would represent a transformation in the treatment of this entire category of disease.

This is not imminent. The CARLYSLE trial is Phase 1. The pathway from Phase 1 safety data to approved therapy typically takes many years. The manufacturing complexity and cost of CAR-T therapy — currently used in cancer at costs of hundreds of thousands of pounds per patient — represents a significant barrier to widespread NHS deployment.

But the principle has been demonstrated. The immune system can be reset. The disease can go into remission from a single infusion. The question is now one of scale, cost, and time — not of whether the biology is possible.

Frequently Asked Questions

What is the lupus immune reset treatment?

CAR-T cell therapy — a treatment originally developed for cancer that is now being tested for severe lupus. The patient's own T cells are extracted, genetically modified in a laboratory to target the B cells driving the autoimmune attack, and returned to the patient in a single infusion. The modified T cells destroy the aberrant B cells, allowing the immune system to reset. Five of six patients in the UCLH-led CARLYSLE trial went into remission within a few months of receiving the treatment.

What is the CARLYSLE trial?

An international Phase 1 clinical trial led by UCL and University College London Hospitals NHS Foundation Trust, sponsored by biopharmaceutical company Autolus. It is the first NHS trial of CAR-T therapy for a condition other than cancer. The trial involves 12 patients globally with severe lupus. The specific therapy being tested is AUTO1/obe-cel — a low-toxicity CAR-T developed by Autolus.

Who are the patients in the trial?

The CARLYSLE trial involves 12 patients globally with severe lupus. The UK patients received their doses at UCLH as part of the international Phase 1 study. One of the UK participants described the experience publicly as the first time there has ever been anything for lupus that represents a possible cure — expressing hope that the results will give people with all autoimmune diseases hope that something is coming their way.

What is lupus?

Systemic lupus erythematosus is a chronic autoimmune disease in which the immune system attacks the body's own healthy tissues, causing inflammation that can affect the kidneys, lungs, heart, brain, joints, and skin. Around 69,000 people in the UK are thought to have the condition. It affects women significantly more than men and is more prevalent and more severe in people of Black African, Caribbean, and Asian descent. Current treatment is immunosuppressive — managing rather than curing the condition.

Could CAR-T therapy work for other autoimmune conditions?

Experts believe so. The mechanism — removing the B cells driving autoimmune attack and allowing the immune system to reset — is potentially applicable to any condition in which B cells are the primary driver of immune dysfunction. Multiple sclerosis has been specifically mentioned. The CARLYSLE results have triggered interest in extending the approach to a broader range of autoimmune conditions. Larger trials across multiple conditions are expected to follow.

When will this treatment be available on the NHS?

The CARLYSLE trial is a Phase 1 study, designed primarily to assess safety and feasibility. The pathway from Phase 1 results to approved NHS therapy typically takes many years and requires Phase 2 and Phase 3 trials confirming efficacy at scale, followed by regulatory approval and NHS commissioning decisions. The manufacturing complexity and current cost of CAR-T therapy — which

runs to hundreds of thousands of pounds per patient in cancer applications — also represents a significant barrier to widespread deployment. The biology has been demonstrated. The timeline to availability for most patients remains uncertain.

The Bottom Line

The CARLYSLE trial results are the most significant development in lupus treatment in decades — and potentially the most significant in autoimmune disease more broadly. A condition that has had no cure, no endpoint, and no mechanism of remission has now produced five patients in remission from a single infusion. The immune system can be reset. The disease can stop.

This is Phase 1 data from 12 patients. The road from here to an approved NHS therapy is long and uncertain. But the principle that has now been demonstrated — that removing the B cells driving the autoimmune attack allows the immune system to restart from a different baseline — is one that the research community believes applies beyond lupus, to the full landscape of autoimmune disease.

For the 69,000 people in the UK with lupus, and the millions more with other autoimmune conditions, the significance of that demonstration is not diminished by the distance between where the research is now and where it needs to go.

Related reading: Cortisol Explained — and How to Reduce It Without Making Things Worse · Ozempic Reduces Breast Cancer Risk by 30%. Here's What That Actually Means. · The £4 Drug That Scientists Think Could Slow Ageing

Popular Articles